

NEBL and AKT1 Maybe New Targets to Eliminate the Colorectal Cancer Cells Resistance to Oncolytic Effect of Vesicular Stomatitis Virus

Zoleikha Mamizadeh

Islamic Azad University Tehran Medical Sciences

Mohamad Reza kalani (✉ kalanimr@yahoo.com)

Golestan University of Medical Sciences and Health Services <https://orcid.org/0000-0002-8756-1200>

Masoud Parsania

Islamic Azad University Tehran Medical Sciences

Mohamad Mehdi Soltan Dallal

TUMS: Tehran University of Medical Sciences

Abdolvahab Moradi

Golestan University of Medical Sciences and Health Services Medical School

Research

Keywords: Colorectal cancer, Oncolytic, Tumor staging, VSV M-protein

Posted Date: May 5th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-437622/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Molecular Therapy - Oncolytics on November 1st, 2021. See the published version at <https://doi.org/10.1016/j.omto.2021.11.013>.

Abstract

Background: Oncolytic virotherapy is a promising therapeutic approach for several cancers which however has been reported that is ineffective in some cases of the same cancer. A well-known oncolytic virus is the Vesicular stomatitis virus (VSV) due to activating the apoptosis mechanism in tumor cells through its Matrix (M) protein. This study compares the different invasive intensity Colorectal tumors for the oncolytic effect of VSV wild type (wt) and M51R M-protein.

Methods: 114 fresh colorectal tumor primary cell cultures plus SW480 and HCT116 colorectal cancer cell lines were examined. Fresh tumor samples were divided into two groups of lower stages (I/II) and higher stages (III/IV) regarding the medical records. The presence of two mutations in the PIK3CA gene, and the expression of NEBL and AKT1 genes were evaluated to biologically compare the staging classification. The cell lines and the stable primary tissue cultures were transfected with a plasmid encoding VSV wild type and M51R mutant M-protein. Western blotting assay confirmed the expression of the protein.

Results: MTT assay results showed either wild type or M51R mutant can kill SW480 and stage I/II primary cultures while mutant M-protein had no apoptotic effects on HCT116 cells and stage III/IV primary cultures. Morphological apoptosis features were observed by a phase-contrast microscope. NEBL and AKT1 expression were significantly higher in resistant cells. Elevated Caspase 9 activity confirmed that the intrinsic apoptosis pathway is the reason for cell death in SW480 cells. The apoptosis rate was quantified and reconfirmed by Annexin V FITC/PI multicolor flow-cytometry.

Conclusions: Different tumors from the same cancer exhibit different sensitivity to M51R M-proteins due to genetic difference. NEBL and AKT1 gene expression may be responsible for this difference which maybe the target of future investigations. Therefore, tumor staging should be considered in oncolytic viral treatment as an interfering factor.

1. Background

Most people are not aware that colorectal cancer (CRC) is going to be the most common cancer worldwide [1, 2]. Common CRC treatments such as surgery, chemotherapy, and radiotherapy have unavoidable disadvantages. Oncolytic virotherapy (OVT) has recently been recognized as a promising therapeutic approach for cancer treatment [3]. Viruses preferentially infect, propagate, and kill tumor cells without causing damage to normal cells [4]. Over the past decade, enormous research has been reported on potential OVs and significant preclinical success.

Some oncolytic viruses are genetically modified to reduce pathogenicity, improve tumor cell selection, and code for therapeutic genes. Vesicular Stomatitis Virus (VSV) is a prototype member of the family rhabdoviruses [4–6]. VSV replicates in the cytoplasm. The VSV genome codes for five proteins: nucleocapsid, phosphoprotein, matrix (M) protein, glycoprotein, and large viral polymerase (7,8). The M-protein is a small molecule consisting of 229 residues (26.6 KDa). This protein is a multifunctional protein and its roles are not restricted to virus assembly and budding (9,10), but also induce cytopathic

effects and apoptosis (10). M-protein restrains host gene expression at three different stages: 1) host transcription inhibition by blocking all three RNA polymerase subclasses, 2) interference with host nucleocytoplasmic RNA transfer, and 3) host translation machinery alteration by the eIF4F complex (11).

It has been proposed that modification of M-protein by substitution of an arginine for a methionine residue at position 51 (M51R) eliminates the virulence of VSV in healthy cells but not in tumor cells (12). Therefore M-protein mutant viruses can be efficient oncolytic agents since they can specifically kill tumor cells *in vivo* without causing disease (13). Previous studies on VSV have shown preclinical success against various types of malignancies such as prostate cancer, breast cancer, melanoma, hepatocellular carcinoma, and glioblastoma (14). Evidence supports each cancer cell line differing in their susceptibility to oncolytic viruses, even if these cancer cells derive from the same tissue type (15). There is controversy about the effect of the M-protein mutant on the induction of apoptosis in different cancer cells. In the present study, the oncolytic potentials of wild-type VSV (wt.) and M51R-mutant M-proteins were compared in human CRC cell lines HCT116 and sw480 using several cytological and proteomics methods.

2. Methods

Briefly, the oncolytic effect of VSV wt and M51R M-protein was compared in SW480 and HCT116 colorectal cancer cells from the different invasive intensity. Primary cell culture was performed from isolated tumor masses from 114 patients at different clinical stages, of which only 38 were stable after 3 passages. SW480 and HCT116 cell lines and 38 CRC primary cell cultures were transfected with a plasmid encoding VSV wt and M51R mutant M-protein. The expression of viral M-proteins confirmed using western blotting assay followed by cell death rate analyzing by MTT assay, observation of cell morphological changes, evaluation of Caspases 3, 8, 9, and flow-cytometry. Each experiment has been repeated at least three times to confirm the accuracy of the results.

We also measured the expression state of three genes which were introduced to be overexpressed or mutated in higher stages or metastatic cases of cancers, Nebulin (NEB) [16], and PIK3CA [17], AKT1 [18] in all of the 114 fresh tumor masses, to confirm the correlation of the invasiveness of the tumor with the effectiveness of the oncolytic VSV treatment. In this regard, Two reported polymorphisms in the exon 9 as E545D/E545K as well as one in the exon 20 as H1047R in the PIK3CA gene were evaluated using RFLP-PCR. Overexpression of NEBL and AKT1 genes also were evaluated using RT-qPCR.

2.1. Fresh tumor samples

After taking the individual consent agreement, we obtained a 3 grams piece of each pathologically confirmed tumor masses isolated from 120 CRC patients of whom only 114 were in an adjacent non-cancerous area, and entered the project. Tumor masses had been resected through colonoscopy by a gastroenterologist or open surgery at the university hospital. Demographic information, Duke's staging, and histopathologic report collected from hospital records after preparation. Primary cell culture was

established from the tumor mass following the previously described protocol [19] of which only 38 were stable after 3 passages.

2.2. Cell lines, plasmids, Transfection

Human colon adenocarcinoma cell lines, HCT116 (C570, RRID:CVCL_0291), SW480 (C506, RRID:CVCL_0546) were selected based on their Dukes' staging, which classified SW480 as stage B (less invasive) and HCT116 cell line as stage D (most invasive) (16). Both cell lines were cultured in RPMI 1640 media (Gibco, Germany) containing 10% FBS with 100 U/ml penicillin and 100 U/ml streptomycin, at 37°C in an atmosphere containing 5% CO₂.

The pCDNA3.1 plasmid (Invitrogen, San Diego, CA, USA) expressing VSV wt and M51R mutant M-proteins was generated. Site-directed mutagenesis applied to produce M51R coding plasmid with the primers which were designed using the New England Biolabs (NEB.com) web server as:

Forward: "GTTGACGAGAaGGACACCTATG"

Reverse: "TCCAAAATAGGATTGTCAATTG"

Hct116 and sw480 cells as well as 38 stable primary cultured cells were seeded in six-well plates at a density of one million cells/well and cultured until the cells reached 80% confluence. Lipofectamine 2000 (Invitrogen) was used for transfection according to the manufacturer's protocol.

2.3. Western blotting

Western blotting was obtained 24, 48, and 72 hrs post-transfection to prove the expression of M-protein in transfected cells. Transfected cells with wt and mutant M-protein plasmid (SW480 and HCT116, as well as 8 primary cell cultures) were lysed in lysis buffer (0.15M NaCl, 1% sodium deoxycholate, 1% Triton X-100, 10nM Tris, pH 7.4) and protease inhibitors (protease inhibitor cocktail set 1; Calbiochem). Total cellular protein content was measured using Bradford's method to confirm the equivalent protein concentration for SDS-PAGE. Consequently, the proteins on the gel were blotted onto nitrocellulose membrane and blocked with 5% skim milk solution. VSV wt and M51R M-proteins were detected as 26 kilodaltons with ECL reagents kit by autoradiography.

2.4. Cytotoxicity Test, MTT Assay

The cytotoxicity of pCDNA-wt, pCDNA-M51R plasmids on HCT116, SW480, and primary cultured cells was assessed using MTT assay. Briefly, cells were seeded 10,000 cells/well on 96-well. After 24 hours, the cells were transfected with pCDNA-wt, pCDNA-M51R plasmids, and empty pCDNA3.1 as a control. Following 24, 48, and 72 hours post-transfection incubation, the media was aspirated and 20 µL of 5 mg/ml MTT dye solution was added per well and incubated at 37°C and 5% CO₂ for 4 hrs. The supernatant was carefully removed and 100 µL of DMSO was added to dissolve the resulting formazan crystals. Optical absorbance at 540 nm was measured using a microplate reader. The cell viability was analyzed as described in previous studies.

2.5. Morphological observation

The cells were grown on tissue culture dishes and then transfected with wt or M51R mutant M-proteins plasmids. The morphological changes of apoptotic cells were observed using a phase-contrast inverted microscope after 24, 48, and 72 hours post-transfection incubation.

2.6. Apoptosis assay: Measurement of Caspase-3, -8, and -9 Activities

The effect of the expression of wt and M51R mutant M-protein on Caspases in HCT116, SW480, and 8 primary cultured cells was determined using the commercially available Caspase-3 (Abcam-colorimetric), Caspase-8 (Abcam- sandwich ELISA), and caspase-9 (abnova-sandwich ELISA) ELISA kit according to the manufacturer's protocol. Due to no detectable M-protein expression observing by western blotting assay after 24 hrs following the transfection, apoptosis assays were performed at 48 and 72 hrs post-transfection.

2.7. Annexin V-FITC/PI by Flow Cytometry

Since such an induced apoptotic process takes time to go through the Annexin assay was conducted after 72 hrs of the transfection. HCT116 and SW480 cells were seeded (250,000 cells/well) in 24-well plates and the apoptosis was measured using the Annexin V-FITC/propidium-iodide (PI) Apoptosis Detection kit (BioLegend) according to the manufacturer's protocol. Following the transfection with wt and M51R M-protein plasmids and incubation for 72 hrs, the cells were washed twice with ice-cold PBS. 1X binding buffer, followed by 10 µL of Annexin-V-FITC, and Subsequently, 10 µL PI was added to each microtube and incubated for 30 min at 4°C in a dark chamber. The apoptosis was analyzed using flow cytometry (BD accuri c6). In the flow-cytometry analysis of Annexin V-FITC/PI double staining, the late apoptotic or necrotic cells were visible in the upper right (UR) and early apoptotic cells in the lower right (LR) quadrants, and live cells in the lower left (LL) quadrants.

2.8. PIK3CA mutation pattern

RFLP-PCR was established for the evaluation of PIK3CA exon 9 mutations, E545K and E545D, and exon 20 mutation, H1047R as described in previous research [21]. The forward primer sequence was "AGAGACAATGAATTAAGGGAAAATGACA", and the reverse primer was "GTCACAGGTAAGTGCTAAATGG" for E545K/D mutation detection. A product of 126bp resulted which using TspRI restriction enzyme could be divided into two fragments of 45 and 81bp if there is no mutation. In case of substitution of the Glutamic acid (E) at the position 545 by Aspartic acid (D) or Lysine (K), the enzyme recognition site will be changed and no digestion occurs, and a single 126bp band is expected in gel electrophoresis assay. The primers for detection of the H1047R mutation are "GGAGTATTCATGAAACAAATGAATGATGCG" as forward and "TTGACTCTTTACTTCGAG" as reverse, which produces a fragment of 126bp as well. Treatment of the products with the FspI restriction enzyme will result in two fragments of 31 and 95bp in case of the presence of a Histidine (H) to Arginine (R) substitution at position 1047. Researchers

previously have reported these mutations to be significantly in correlation with higher stages of tumor [17, 21, 22].

2.9. NEBL expression levels

Nebulette (NEBL) is a cytoskeletal matrix protein expressed in several tissues. Up-regulation of the NEBL gene was reported in several cancers of metastatic and higher stage[16, 23]. We have evaluated the expression of this gene in colorectal cancer in 114 CRC tumor masses comparing the non-cancerous marginal tissues. Total RNA was extracted from all samples using the ZymoResearch miniprep RNA extraction kit according to the manufacturer's protocol. The quantitative relative reverse transcriptase, real-time polymerase chain reaction (RT-qPCR) with SYBR Green was performed in a CFX96 Bio-Rad Real-Time PCR instrument. Based on previous research projects, the forward primer sequence was "CACCAAATCTAAGGACCTACCG" and the reverse primer was "CTCAATGTAATTGCTGGGAGC", which expected to result in a product length of 176bp [16]. GAPDH was used as the reference gene (primers F: "TCCCATCACCATCTTCCA", R: " CATCACGCCACAGTTCC", product length: 376bp). All samples were assayed in triplicates. The PCR cycling conditions were: primary 95°C for 10 min, 40 cycles of 95°C for 10 seconds, 60°C for 30 seconds, and 72°C for 45 seconds, followed by a final elongation step of 72°C for 10 minutes. A final step of melting curve analysis at 65°C increasing 0.5°C every 5 seconds up to 95°C conducted to confirm the results. The standard comparing threshold cycle (Ct) value changes ($\Delta\Delta Ct$) was applied to analyze the results using the $2^{-\Delta\Delta Ct}$ method.

2.10. AKT1 expression levels [18]

Alpha- Serine/Threonine Kinase 1 (AKT1) is also reported to overexpress in higher-stage tumors including colorectal malignancies [18, 23, 24]. To examine the AKT1 gene expression, the extracted total RNA from 114 tumor samples and paired normal tissues were used for the SYBR Green RT-qPCR assay. The forward primer was "TCTATGGCGCTGAGATTGTG" and the reverse primer was "CTTAATGTGCCGTCTTGT", which is expected to produce a product of 116bp. GAPDH was used as the reference gene and all samples were assayed in triplicates. The PCR program was: a primary denaturation of 95°C for 10 min, 40 cycles of 95°C for 10 seconds, 60°C for 30 seconds, and 72°C for 30 s, followed by a final step of melting curve analysis at 65°C increasing 0.5°C every 5 seconds up to 95°C. The standard comparing threshold cycle (Ct) value changes ($\Delta\Delta Ct$) was applied to analyze the results, somehow a lower $\Delta\Delta Ct$ value suggested a higher expression level.

3. Results

3.1. Fresh tumor analysis

The youngest and oldest patients were 36 and 84 years old respectively with an average of 55.6 years, consist of 58 male and 56 female patients. Most of the samples were resected from descending colon (72 cases) comparing transverse colon (29 cases) and ascending colon (13 cases) (Table 1). Only 38 of 114 Primary cell cultures were stable after 3 passages in which 23 were successfully transfected by the

constructed plasmid. Fig. 1 shows the results of the PIK3CA gene polymorphisms and the expression of AKT1 and NEBL in 114 tumor and adjacent normal tissues.

Table 1

Statistical results for two PIK3CA gene polymorphisms, and the fold change of expression of the AKT1 and NEBL genes in 114 cancer and 114 adjacent normal tissues.

		PIK3CA, E545D/K			PIK3CA, H1047R			NEBL		AKT1	
Total		Wild	Mutant	Cancer	Wild	Mutant	Cancer	vs.	cancer	vs.	cancer
		Cancer	normal	normal	normal	normal	normal	normal	expression	expression	
	Cancer										
Stage I/II	38	42	20	29	18	13	24	38	14	4	+0.2 fold
	p-value=	p-value=	p-value=				p-value=	p-value=			+0.3 fold
	0.6	0.07	0.06				0.06	0.01			
Stage III/IV	76	72	8	42	68	30	12	41	64	31	+3.7 fold
	p-value=	p-value=	p-value=				p-value=	p-value=			+2.2 fold
	0.8	0.0001	0.0001				0.0002	0.0001			

3.2. Western blot analysis

The expression of wt and M51R VSV M-protein was validated by Western blotting. Transfection of the cells with pCDNA-wt and pCDNA-M51R M-protein plasmids resulted in detectable expression of the M-protein using an anti-M monoclonal antibody, after 48 and 72 hrs of incubation. However, the protein expression bands were clearer at 72 hrs comparing 48 hrs post-transfection. The bands were hardly detectable after 24 hrs post-transfection. A distinct band was seen about 26 kDa in transfected cells, but not in the non-transfected ones. (Fig.2)

3.3. Cytotoxicity Test-MTT Assay

As shown in Fig.3, the viability of Hct116, SW480, and all of 23 primary cultured cells was reduced by at least 67% when were transfected with 200 ng pCDNA-wt plasmid compared to the untransfected cells. The viability of the mutant M-protein expressing SW480 cells and 12 stages “I/II” primary cultured cells

was observed to be decreased as well. However, no considerable disrupted cells were observed in 11 stages “III/IV” primary cultured and Hct116 cells expressing M51R mutant protein. Experiments were repeated three times and the same results were observed.

3.4. Caspase-3, – 8, and – 9 activity assays

A three folds increase in caspase 9, as well as two folds increase in caspase-8 concentration, were observed in two cultured cell lines (SW480, HCT116) which express wt M-protein comparing control cells. As showed in Fig.4, in HCT116 cells like four of stage C/D primary cultured CRC cells, the level of caspase-3 was about three folds more than cells transfected with empty pCDNA3.1 after 48 hrs and it slightly increased after 72 hrs. The SW480 cells transfected with M51R plasmid resulted in a caspase-8 activity depletion from 48 hrs to 72 hrs post-transfection, its level is almost the same as cells transfected with empty plasmid. The same results of caspase-8 activity depletion were observed in four primary cultured CRC cells of stage A which were expressing M51R M-protein. Furthermore, the activity of caspase-9 was almost equal to cells transfected with empty plasmid after 48 hrs and was dramatically elevated about 2 folds for 72 hrs either in SW480 or the four A stage CRC cells. Interestingly, no considerable changes were seen in the concentration of either caspase-8 or -9. Caspase-3 was decreased slightly in HCT116 cells from 48 to 72 hrs post-transfection with M51R M-protein plasmids. These changes will more interpret at discussion (Fig.4).

3.5. Morphological changes in cells

The apoptotic shrunk cells can be observed detached from the surface and appear to be float in the medium. Most of the cells remained attached to the surface with a cone shape after 24 hrs post-transfection, which represents an alive and healthy condition. After 48 hrs, some round shape floating cells were observed (Fig. 5).

3.6. Flow cytometric assays for Annexin V-FITC/PI

Flowcytometric Annexin V-FITC/PI assays were performed after 72 hrs post-transfection. Cells double-stained for Annexin V and PI to discriminate the cells in the earlier stages of apoptosis (annexin V-FITC positive, PI negative) from those in later stages of apoptosis or that were already dead (annexin V–FITC positive, PI positive).

Most of the cells, 92.3%, and 97.9% were viable in non-transfected SW480 and HCT116 cells, respectively. The count of the apoptotic cells increased in both cell lines which were transfected with pCDNA-wt M-protein. 7.3%, 73.5%, and 19.1% of viable, early apoptosis, and late apoptosis were detected in SW480 cells expressing wt M-protein respectively (Fig. 6). Meanwhile, these same rates were 15.3%, 56.6%, 28.1% for the HCT116 cells expressing wt M-protein (Fig. 6, middle-down).

In the M51R M-protein expressing cell lines 20.5% of the cells were viable for SW480, and 79.1% for HCT116 cells. While the cells which underwent early apoptosis were, 5.3% and 8.9% for SW480 and HCT116 cell lines, respectively (Fig. 6).

4. Discussion

VSV is a potent oncolytic virus candidate (17). VSV-M-protein plays essential roles in virus assembly as well as the cytopathic effect on host cells by disruption of the host cytoskeleton. Moreover, M-protein is responsible for apoptosis in the host cell through inhibition of transcription through host RNA polymerase dumping as well as interruption of nucleocytoplasmic transport of RNAs (18–20). Researchers have identified wild M-protein as the key harmful molecule for infected cells [11].

However, there is controversy about the effectiveness of the M-protein mutant. Several researchers reported no significant oncolytic effects for M-protein apart from viral particles. These researchers believe a fundamental role of other viral components in addition to M-protein for induction of apoptosis (21,22), while others have noted apoptosis in cells with extra-expression of recombinant M-protein (11,23–26). Gaddy et al described that M-protein itself can interfere with the nucleus transcription [11]. Likewise, our previous work illustrated the effects of recombinant VSV M-protein on apoptosis in CRC SW480 cells (25). Douzandegan et al have also reported both VSV wt and M51R M-protein provoke apoptotic cell death in KYSE-30 esophagus cancer cells (26).

Similar controversy has been proved on prostate cancer cells. Researchers have reported that LNCaP prostate cancer cells are sensitive to VSV, while PC3 prostate cancer cells are resistant to this virus (27,28). Other reports have demonstrated the diverse effects of wt and mutant M-proteins in human CRC cell lines. ARKO cells showed high sensitivity, LoVo cells were resistant, whereas HCT116, has limited susceptibility to VSV (17). This proposes the idea that different cancer cells exhibit different susceptibility to oncolytic viruses and therefore the need to investigate the mechanism.

In the present study, we analyzed the oncolytic effect of wt and M51R VSV M-proteins on two human CRC cell lines of different cancer stages. Western blot analysis was performed to confirm the expression of wt and M51R M-proteins in transfected cells at 24, 48, and 72 h post-transfection. As mentioned in the results very thin band was visible at 26 KDa position at 24 hrs which represents a very low concentration of expressed M-protein. These specific bands were more visible and widened from 48 to 72 hrs which may describe the increase of the M-protein expression (Fig. 2). An increasing cell death rate is expected with this increasing M-protein concentration. The MTT Assay can validate this hypothesis.

As determined by the MTT assay, SW480 cells expressing wt and M51R proteins show a significant increase in cell death compared to control cells either 24, 48, or 72 hours post-transfection. HCT116 cells treated with wt M-protein showed a 45% decrease while no considerable cytotoxic effect was observed for cells expressing M51R protein. These results suggested that the expression of mutant M-protein in HCT116 cells may not affect cell viability.

As seen in Fig. 3, the amount of plasmid used for transfection of cells was optimized with 100 and 200 ng of plasmids. The amount of applied plasmid does not affect cell viability in the HTC116 cell line. While in the SW480 cells, the more applied plasmid (200ng) coefficient with less viable cells either after 24, 48, or 72 post-transfection. This different sensitivity to the number of transfection plasmids suggests a significant difference between the physiopathology of the two case study cell lines.

To investigate this physiopathology difference, the Caspases-3, -8, and - 9 levels were evaluated. This is well known that Caspases-8 involve in the extrinsic pathway and Caspase-9 activates via the intrinsic apoptosis pathway. Caspase-3 is an execution enzyme that activates in response to caspase-8 or -9 activations and is considered a hallmark of apoptosis [29, 30].

Our experiment showed that the caspase response to wt M-protein expression was similar in either the SW480 or HCT116 cell line, including a dramatic elevation of Caspase-9 and – 3 and slightly in Caspase-8 (Fig. 4). However, mutant M-protein results in no considerable increase of Caspases-3, -8, or -9 in HCT116 cells. Meanwhile, SW480 cells expressing M51R M-proteins showed higher activity of Caspases-3 and – 9. Similarly, in several studies, Caspase-9 has been reported as the dominant enhancing component of apoptosis in the presence of M-protein (5,29,30). Other researchers have also reported this prominent role for caspase-9 in flaring up the apoptosis cascade due to wt M-protein activity in HeLa and BHK cells (21,22,31).

Gaddy et al have two different hypotheses for the mechanism of apoptosis in response to M51R M protein expression. They report Caspase-9 and intrinsic pathway as the main mechanism in their primary studies while introducing caspase-8 as the most important apoptotic pathway following M51R M-protein expression in the presence of viral particles (11,32). Our observations also verified the effect of caspase-9 and intrinsic pathways on apoptosis due to M51R-M expression in the lower stage but not in higher stage cancer cells.

Previous studies have shown that VSV-ΔM51 M-protein can initiate apoptosis in most PDAC cell lines except for three, Hs766T, HPAC, and HPAF-II which were resistant to apoptosis and showed no or low amount of Caspase-8 and Caspase-9. We explore the difference between these cell lines and found that these three cell lines are also originated from the higher cancer stages (32).

Kopecky, as well as Gaddy, suggested that apoptosis induced by mutant M-protein is due to the expression of some new genes in the host cell that are responsible for mitochondrial cell switching death, whereas apoptosis is caused by wt M-protein is due to global inhibition of host gene expression (11,31,33). However, in one study examining the effect of different VSV M-proteins on host gene expression in human embryonic kidney BHK21 cells, it was reported that the substitution of Methionine 51 with Arginine weakened the apoptotic potential of M-protein to the minimum level and lead to the halter caspase-3 induction (34).

Furthermore, flow cytometry with Annexin V/PI staining confirmed that the cytotoxicity of the expressed M-protein correlates with the induction of apoptosis. Based on flow cytometric results, wt VSV M-protein

induces apoptosis in both SW480 and HCT116 cells while M51R only has an apoptotic effect on SW480 cells.

According to this different apoptotic susceptibility, Mouradov et al reported a clear distinction between CRC cell lines. They have extensively studied 70 CRC cell lines for mutations and molecular differences (35). They categorized cell lines into eminent hypermutated and non-hypermutated groups in terms of mutations ranging from 6.6 to 260 per million base pairs. Based on their results, 86.3% of hypermutated cell lines such as HCT116 exhibited high microsatellite instability (MSI), a higher number of insertion/deletion (41.1-fold; $P < 0.001$), and single nucleotide polymorphisms (9.7-fold); $P < 0.001$) comparing non-hypermutant cell lines such as SW480 (35).

The mutations and molecular differences of cancer cells have a significant impact on the stage of cancer, and therefore, treatment and prognosis. The Dukes' staging for CRC has been mentioned in several reports which classified SW480 as stage B and HCT116 cell line as stage D. Dukes' stage D represents a metastatic and more invasive cancer. Dukes' B stage restricts the muscle layer and is therefore a less invasive tumor (16).

Regarding the cellular and molecular differences of tumor cells at various stages, two promising hypotheses need to be investigated in future works. Berg et al in 2017 reported a severe up-regulation of AKT pathway genes in SW480 but not in HCT116 cells (36). Dunn and Connor in 2011 showed that viral M-protein can inactivate AKT (37). The first hypothesis is that the apoptotic response of SW480 cells to mutated M-protein may be explained by inhibition of AKT via M-protein and consequently increased apoptosis. As the second hypothesis, SW480 cells have several mutations in the TP53 gene while HCT116 harbored wt TP53 (16). Moreover, HCT116 showed lower BCL-2 family activity comparing SW480 Cells (30,38). Furthermore, previous research has reported the M-protein effects on BCL suppression (18). This difference in BCL and TP53 may be another reason for the responsiveness of HCT116 cells to wt M-protein and not to mutant one, so it may be referred to as BCL/TP53 hypotheses. The SW480 may be the better target for the M51R M-protein due to having more BCL activity. The present work reconfirmed the second hypothesis where the apoptosis of SW480 cells in the presence of the mutant M-protein by flow-cytometry method (Fig. 6, upper right, right).

5. Conclusion

Our results suggest that the oncolytic effects of a virus on cells even derived from the same origin may be related to the different molecular and genetic characteristics of the cells. The degree of cell differentiation may be the key factor correlating with the efficacy of M51R M-protein in SW480 cells and not in HCT116, where SW480 belongs to a better differentiated and less mutated group, and HCT116 is a metastatic tumor cell and belongs to the hypermutated cell group (35). Therefore, tumor staging should be considered as an interfering factor in oncolytic viral cancer treatment approaches.

Abbreviations

- Vesicular stomatitis virus (VSV)
- Matrix protein (M-protein)
- wild type (wt)
- colorectal cancer (CRC)
- Oncolytic virotherapy (OVT)

Declarations

- **Ethics approval and consent to participate**

This project was approved by the Research Ethics Committee of the GoUMS. Individual consent agreements were obtained from 120 CRC patients for using a piece of the resected tumor mass in this project.

- **Consent for publication**

No individual person's data was included in this project.

- **Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

- **Competing interests**

The authors declare that they have no conflict of interest.

- **Funding**

There is no funding for this project.

- **Authors' contributions**

Experiments, analysis, manuscript preparation (ZM and MRK), intellectual, planning the project, supervision, manuscript editing (AM and MRK), scientific consultant (AM, MRK, MMSD and MP)

- **Acknowledgements**

This work was conducted at the Department of Microbiology, Medical College of the Golestan University of Medical Sciences with the personal financial resource.

References

1. Rafiemanesh H, Pakzad R, Abedi M, Kor Y, Moludi J, Towhidi F, et al. Colorectal cancer in Iran: epidemiology and morphology trends. EXCLI J 15Doc738 ISSN 1611-2156 [Internet]. 2016 [cited 2020 Jan 7]; Available from: https://www.excli.de/vol15/Salehiniya_28112016_proof.pdf
2. Ansa B, Coughlin S, Alema-Mensah E, Smith S. Evaluation of Colorectal Cancer Incidence Trends in the United States (2000–2014). *J Clin Med.* 2018;7:22.
3. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci.* 2016;107:1373–9.
4. Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. *J Gen Virol.* 2012;93:2529–45.
5. Bishnoi S, Tiwari R, Gupta S, Byrareddy S, Nayak D. Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. *Viruses.* 2018;10:90.
6. Irie T, Carnero E, Okumura A, García-Sastre A, Harty RN. Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo. *J Gen Virol.* 2007;88:2559–67.
7. Redondo N, Madan V, Alvarez E, Carrasco L. Impact of vesicular stomatitis virus M proteins on different cellular functions. *PloS One.* 2015;10:e0131137.
8. Kuss S, Mata M, Zhang L, Fontoura B. Nuclear imprisonment: viral strategies to arrest host mRNA nuclear export. *Viruses.* 2013;5:1824–49.
9. Gaudier M, Gaudin Y, Knossow M. Crystal structure of vesicular stomatitis virus matrix protein. *EMBO J.* 2002;21:2886–92.
10. Wollmann G, Rogulin V, Simon I, Rose JK, van den Pol AN. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. *J Virol.* 2010;84:1563–73.
11. Gaddy DF, Lyles DS. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. *J Virol.* 2005;79:4170–9.
12. Russell L, Peng K-W. The emerging role of oncolytic virus therapy against cancer. *Chin Clin Oncol.* 2018;7:16–16.
13. Ahmed M, Patel CM, Fehl DJ. The use of oncolytic vesicular stomatitis virus in conjunction with natural products for the treatment of cervical cancers. *Adv Tech Biol Med.* 2015;3:1–6.
14. Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, et al. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. *J Virol.* 2012;86:3073–87.
15. Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS. Changes in susceptibility to oncolytic vesicular stomatitis virus during progression of prostate cancer. *J Virol.* 2015;89:5250–63.
16. Hosseini SM, Mahjoubi F, Majidzadeh T, Khaje-Hosseini F, Haghpanah M. Nebulette Expression Is Associated with Lymph Node Metastasis in Patients with Colorectal Cancer. *Middle East J Dig Dis.* 2018;10:174–9.

17. Reggiani Bonetti L, Barresi V, Maiorana A, Manfredini S, Caprera C, Bettelli S. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer. *Dis Markers*. 2018;2018:1–9.
18. Heng J, Guo X, Wu W, Wang Y, Li G, Chen M, et al. Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients. *PLOS ONE*. Public Library of Science; 2017;12:e0174022.
19. Sato T, Clevers H. Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications. *Science*. American Association for the Advancement of Science; 2013;340:1190–4.
20. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. *Oncogenesis*. 2013;2:e71.
21. Ranjbar R, Mohammadpour S, Esfahani AT, Namazian S, Yaghob-Taleghani M, Baghaei K, et al. Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients. *Gastroenterol Hepatol Bed Bench*. Shahid Beheshti University of Medical Sciences; 2019;12:S22.
22. Li W-M, Hu T-T, Zhou L-L, Feng Y-M, Wang Y-Y, Fang J. Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method. *BMC Cancer*. 2016;16:454–65.
23. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. *Carcinogenesis*. 2005;26:1503–12.
24. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, et al. Novel Expression Patterns of PI3K/AKT/mTOR Signaling Pathway Components in Colorectal Cancer. *J Am Coll Surg*. 2010;210:767–78.
25. Stewart IV JH, Ahmed M, Northrup SA, Willingham M, Lyles DS. Vesicular stomatitis virus as a treatment for colorectal cancer. *Cancer Gene Ther*. 2011;18:837.
26. Desforges M, Despars G, Bérard S, Gosselin M, McKenzie MO, Lyles DS, et al. Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by vesicular stomatitis virus. *Virology*. 2002;295:63–73.
27. Rajani KR, Kneller ELP, McKenzie MO, Horita DA, Chou JW, Lyles DS. Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription. *PLoS Pathog*. 2012;8:e1002929.
28. Zhang H, Wen YJ, Mao BY, Gong QY, Qian ZY, Wei YQ. Plasmid encoding matrix protein of vesicular stomatitis viruses as an antitumor agent inhibiting rat glioma growth in situ. *Exp Oncol*. 2007;
29. Kopecky SA, Willingham MC, Lyles DS. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. *J Virol*. 2001;75:12169–81.
30. Kiechle FL, Zhang X. Apoptosis: biochemical aspects and clinical implications. *Clin Chim Acta*. 2002;326:27–45.
31. Glodowski DR, Petersen JM, Dahlberg JE. Complex nuclear localization signals in the matrix protein of vesicular stomatitis virus. *J Biol Chem*. 2002;277:46864–70.

32. Black BL, Lyles DS. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. *J Virol.* 1992;66:4058–64.
33. Gray Z, Tabarraei A, Moradi A, Kalani MR. M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells. *Mol Biol Rep.* 2019;1–9.
34. Douzandegan Y, Tahamtan A, Gray Z, Nikoo HR, Tabarraei A, Moradi A. Cell Death Mechanisms in Esophageal Squamous Cell Carcinoma Induced by Vesicular Stomatitis Virus Matrix Protein. *Osong Public Health Res Perspect.* 2019;10:246.
35. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. *Virology.* 2004;330:34–49.
36. Carey BL, Ahmed M, Puckett S, Lyles DS. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. *J Virol.* 2008;82:12104–15.
37. Samuel S, Tumilasci VF, Oliere S, Nguyễn TL-A, Shamy A, Bell J, et al. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. *Mol Ther.* 2010;18:2094–103.
38. Sharif-Askari E, Nakhaei P, Oliere S, Tumilasci V, Hernandez E, Wilkinson P, et al. Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. *Virology.* 2007;365:20–33.
39. Kopecky SA, Lyles DS. Contrasting Effects of Matrix Protein on Apoptosis in HeLa and BHK Cells Infected with Vesicular Stomatitis Virus Are due to Inhibition of Host Gene Expression. *J Virol.* 2003;77:4658–69.
40. Felt SA, Moerdyk-Schauwecker MJ, Grdzelishvili VZ. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. *Virology.* 2015;474:163–73.
41. Gaddy DF, Lyles DS. Oncolytic Vesicular Stomatitis Virus Induces Apoptosis via Signaling through PKR, Fas, and Daxx. *J Virol.* 2007;81:2792–804.
42. Kim GN, Kang CY. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression. *Virology.* 2007;357:41–53.
43. Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. *Cancer Res.* 2014;74:3238–47.
44. Berg KC, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, et al. Multi-omics of 34 colorectal cancer cell lines-a resource for biomedical studies. *Mol Cancer.* 2017;16:116.
45. Dunn EF, Connor JH. Dominant inhibition of Akt/protein kinase B signaling by the matrix protein of a negative-strand RNA virus. *J Virol.* 2011;85:422–31.
46. Wang Y-B, Zhao X-H, Li G, Zheng J-H, Qiu W. MicroRNA-184 inhibits proliferation and promotes apoptosis of human colon cancer SW480 and HCT116 cells by downregulating C-MYC and BCL-2. *J Cell Biochem.* 2018;119:1702–15.

Figures




Figure 1

Comparison of stages "I/II" vs. "III/IV" for two PIK3CA gene polymorphisms (RFLP-PCR), and the expression of AKT1 and NEBL genes (RT-qPCR) in 114 cancer and 114 adjacent normal tissues.




Figure 2

Western blotting M-protein expression of wt (left) and M51R (middle) in transfected HCT116 (A, C) and SW480 (B, D) cells which were carried out at 48 and 72 hrs post-transfection. Commercial M-protein was used as the positive control (A, B, C, D, right column).




Figure 3

MTT assay (average of three times repeat), cell viability of SW480 and HCT116 cells transfected with 100 ng and 200 ng, (24, 48, and 72 h post-transfection) was determined by MTT assay. Cells transfected with empty plasmids were considered as control cells.




Figure 4

Activity of caspase-3, caspase-8, and caspase-9 (average of three times repeat). Transfected SW480 cells with wt and M51R M-protein showed an increase of caspase-3 and 9 representing the intrinsic apoptosis pathway compared to untransfected cells (up). Transfected HCT116 cells with wt showed an increase in caspase-3, 8, and 9 while cells expressing M51R M-protein did not show any significant increase of caspase 3, 8, or 9.




Figure 5

Cell morphology of HCT116 (up) and SW480 (down) cells after 72 hrs post-transfection, in control (left), Wt (middle), and M51R M-protein expressing cells (right), showed cell rounding, shrinking and detachment from the surface.




Figure 6

Annexin, FITC/PI flow-cytometry, shows apoptosis in either SW480 or HCT116 cells expressing wt M-protein (middle column), but only in SW480 cells expressing M51R mutant M-protein (right column). (All experiments were repeated three times)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- qPCR.docx